The mitotic inhibitor eribulin was examined in an EORTC phase 2 trial of patients with STS stratified by subtype and met prespecified statistical boundaries for the primary endpoint of PFS at 12 weeks for both leiomyosarcoma and adipocytic sarcoma.100 Eribulin is currently being evaluated in a phase 3 clinical trial for patients with advanced, refractory STS.101 ABT-510, a peptide that mimics the antiangiogenic activity of thrombospondin-1, was tested in a phase 2 trial in patients (N = 88) with locally advanced or metastatic STS. This evidence concerns the gene THBS1 and telomere syndrome.